Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
598.00    -6.00 (-0.99%)
Bid:
596.00
Ask:
598.00
Spread: 2.00 (0.336%)
Market Cap: £521.00m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Victrex plc Full Year Trading Statement

6 Oct 2020 07:00

RNS Number : 1594B
Victrex PLC
06 October 2020
 
 

 

 

6 October 2020

Victrex plc: Full year trading update

'End markets remain subdued into FY 2021'

Victrex plc, an innovative world leader in high performance polymer solutions, today releases a trading update following the end of its 2020 financial year on 30 September 2020.

At the close of the Group's FY 2020 financial year, trading overall remains subdued, although some end markets have slightly improved from trough levels. Aerospace and Energy volumes have remained in line with the lows seen during Q3, with some limited incremental improvement in Automotive and Medical monthly run rates, although Value Added Resellers - which saw growth during Q3 - was softer during the fourth and final quarter.

 

Q4 and FY 2020 performance

Overall, Q4 Group sales volume was down 26% to 695 tonnes (Q4 2019: 940 tonnes), with Group revenue down 27% to £55.7m (Q4 2019: £76.2m), in line with expectations.

For FY 2020 as a whole, Group sales volume of 3,492 tonnes was down 7% compared to the prior year (FY 2019: 3,751 tonnes), with Group revenue of £266m down 10% (FY 2019: £294m).

Whilst top-line performance for FY 2020 was slightly ahead of consensus expectations, our high fixed cost base and the under-absorption of fixed costs due to lower production volumes will mean an impact on margin, as previously communicated. During Q4 we announced a cost saving plan that will partially mitigate this, but notwithstanding this, the effect of lower production versus sales volumes will continue through FY 2021 as volumes remain low due to end market demand, inventory is gradually unwound after Brexit and reflecting the planned debottlenecking programme, with a proportion of capacity taken offline.

Mega-programme progress

Through its Polymer & Parts strategy, Victrex continues to focus on delivering further milestones in its growth pipeline, as well as exploring options to drive growth within the PAEK family of polymers or related technologies.

 

Despite the current challenges in Aerospace, our TxV composite parts facility in the US has secured repeat commercial orders which reflect the benefit of our technology in being able to efficiently manufacture strong and light-weight composite parts for a range of applications. In Magma, work is progressing with TechnipFMC, as part of the qualification programme in Brazil, with testing data confirming PEEK as the preferred material of choice. Additional projects including m-pipe jumper lines for Caltex Oil Tools in the Gulf of Mexico and a successful deployment project in the North Sea have also been supported. Whilst relatively small, both projects continue to validate the performance and cost benefits of PEEK based composite materials in a lower-oil price environment.

 

In Medical, with the Knee clinical trial in Italy having resumed following a pause due to COVID-19, our partners are also progressing registration to extend the trial, including in India, as we seek to further validate the proposition.

 

Financial position and cost management

Our net cash position at 30 September 2020 was £67.4m, which excludes £5.6m ring-fenced for our China manufacturing subsidiary. The Group has an undrawn and committed RCF of £20m, together with a £20m accordion facility.

 

As previously communicated, Victrex has been reviewing additional cost actions and efficiencies to support profitability in a lower production environment. As part of this programme, we commenced consultation in Q4 which would reduce our employee base by up to 100 roles, primarily through voluntary severance. The majority of these roles are within UK polymer manufacturing and will not impact the resources needed to deliver our long-term growth programmes. Once fully concluded, we expect this programme will partially mitigate the impact from under-absorbed fixed costs and help to support margin in FY 2021 and beyond. As part of the voluntary severance programme, we expect to incur an exceptional charge of approximately £9.5m to be taken in the FY 2020 accounts. With exceptional items already incurred relating to our China manufacturing investment in the first half, total exceptional items for FY 2020 are expected to be in the order of £12m.

 

Dividends

The capital requirements for our UK debottlenecking and China manufacturing subsidiary, as well as our usual ongoing maintenance capital expenditure, are likely to be in excess of £50m in FY 2021. These requirements will be covered by our cash generation and, in the light of a healthy net cash position, the Board expects to reinstate a dividend for FY 2020.

 

Outlook

At the start of FY 2021, trading overall remains subdued, although some end markets have slightly improved from trough levels. Whilst COVID-19 headwinds continue to impact trading, our focus continues to be on the safety, health and well-being of our employees, delivering good customer service and managing our costs.

 

In the immediate short term, we anticipate our end markets will remain around the levels seen in Q4 and we will also see the continuing effects on margin from lower production as inventories are gradually unwound through FY 2021. H1 2021 is also likely to see a tough comparative against the solid performance in H1 2020. There is also the possibility of uncertainty from the Brexit outcome, although our contingency plans with additional warehousing and high inventories keep us in a good position to continue to support our customers.

Overall, with sustainable products, our range of medium to long term growth opportunities remain strong, our financial position is robust and our cash generation capabilities offer the opportunity of good medium term returns to shareholders.

 

Victrex will release its FY 2020 Preliminary results on Wednesday 9 December 2020.

 

Victrex plc:

Andrew Hanson, Director of Investor Relations +44 (0) 01253 898121/07809 595831

Jakob Sigurdsson, Chief Executive +44 (0) 1253 897700

Richard Armitage, Chief Financial Officer +44 (0) 1253 897700

 

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions, focused on the strategic markets of automotive, aerospace, energy (including manufacturing & engineering), electronics and medical. Every day, millions of people use sustainable products and applications, which contain our materials - from smart phones, aeroplanes and cars to oil and gas operations and medical devices. With over 40 years' experience, we develop world leading solutions in PEEK and PAEK based polymers, semi-finished and finished parts which shape future performance for our customers and our markets, support environmental and societal benefits and drive value for our shareholders. Find out more at www.victrexplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTMABRTMTAMBRM
Date   Source Headline
30th Jun 20251:38 pmRNSTotal Voting Rights
30th Jun 20259:13 amRNSDirector Declaration
18th Jun 20257:00 amRNSAppointment of Joint Corporate Broker
3rd Jun 20251:56 pmRNSHolding(s) in Company
2nd Jun 202511:34 amRNSBlock listing Interim Review
2nd Jun 202510:25 amRNSHolding(s) in Company
30th May 20259:50 amRNSTotal Voting Rights
27th May 202512:40 pmRNSHolding(s) in Company
13th May 20253:30 pmRNSDirector/PDMR Shareholding
12th May 20257:00 amRNSVictrex plc – Interim Results 2025
7th May 20257:00 amRNS‘Magma’ advances via TechnipFMC award
30th Apr 202511:00 amRNSTotal Voting Rights
31st Mar 20259:17 amRNSTotal Voting Rights
21st Mar 202510:34 amRNSDirector/PDMR Shareholding
28th Feb 20259:55 amRNSTotal Voting Rights
19th Feb 20259:00 amRNSAdditional Listing
7th Feb 20251:54 pmRNSResult of AGM
7th Feb 20257:00 amRNSAGM and Trading Update
31st Jan 20259:17 amRNSTotal Voting Rights
21st Jan 20251:56 pmRNSHolding(s) in Company
6th Jan 20251:00 pmRNSAnnual Financial Report
31st Dec 20249:00 amRNSTotal Voting Rights
16th Dec 20248:52 amRNSDirector/PDMR Shareholding
11th Dec 20243:07 pmRNSDirector/PDMR Shareholding
10th Dec 202411:46 amRNSDirector/PDMR Shareholding
10th Dec 20249:28 amRNSHolding(s) in Company
3rd Dec 202410:58 amRNSDirector/PDMR Shareholding
3rd Dec 20247:00 amRNSVictrex plc - Preliminary Results 2024
2nd Dec 20249:38 amRNSBlock listing Interim Review
29th Nov 20249:07 amRNSTotal Voting Rights
14th Nov 20249:31 amRNSHolding(s) in Company
31st Oct 202412:25 pmRNSTotal Voting Rights
14th Oct 20243:09 pmRNSHolding(s) in Company
30th Sep 20241:44 pmRNSTotal Voting Rights
27th Sep 20249:22 amRNSHolding(s) in Company
24th Sep 202411:24 amRNSDirector/PDMR Shareholding
17th Sep 20242:00 pmRNSUS FDA approval: Total Knee Study
12th Sep 202411:18 amRNSDirector/PDMR Shareholding
3rd Sep 20244:20 pmRNSHolding(s) in Company
30th Aug 20243:44 pmRNSDirector/PDMR Shareholding
30th Aug 20249:16 amRNSTotal Voting Rights
23rd Aug 20243:18 pmRNSHolding(s) in Company
9th Aug 202410:08 amRNSHolding(s) in Company
5th Aug 20241:56 pmRNSDirector/PDMR Shareholding
2nd Aug 202411:51 amRNSDirector/PDMR Shareholding
1st Aug 20241:20 pmRNSDirector/PDMR Shareholding
31st Jul 202412:20 pmRNSTotal Voting Rights
5th Jul 20242:02 pmRNSDirector/PDMR Shareholding
4th Jul 20247:00 amRNSQ3 Interim Management Statement
28th Jun 20249:52 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.